Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
Status:
Completed
Trial end date:
2020-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate if tralokinumab changes the metabolism of
selected CYP substrates in adults with moderate-to-severe AD after:
- 14 weeks of treatment with tralokinumab
- a single dose of tralokinumab